Os 189 melhores médicos de PET/TAC do mundo

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

O Dr. Erkan Göcen é especialista em Oncologia Radioterápica no Hospital Privado Çerkezköy Optimed (Optimed Health Group). Formou-se na Universidade de Istambul, Faculdade de Medicina (Çapa), em 2003.

Carreira: Treinou e praticou em Oncologia Radioterápica de 2010 a 2012. Trabalhou em instituições de saúde públicas e privadas de 2012 a 2016. Trabalhou no setor médico privado como especialista em Oncologia Radioterápica de 2016 a 2023. Está no Hospital Optimed desde 2024.

Interesses clínicos: cânceres de cérebro, cabeça e pescoço, esôfago, estômago, colorretal, pâncreas, próstata, bexiga, pulmão, tecidos moles (sarcomas), pele, útero e colo do útero, e mama. Afiliações: Sociedade Turca de Oncologia Radioterápica (TROD) e Câmara Médica de Tekirdağ. Idiomas: inglês e turco.

Dr. Shute Ailia DAE is a medical oncologist at Optimed International Çorlu Hospital. Dr. Ailia graduated from Dokuz Eylül University Faculty of Medicine in 2013 and completed an internal medicine residency at Bezmialem Vakıf University Hospital in 2018. A hematology–oncology fellowship at Başkent University Hospital followed in 2023.

From 2018 to 2020, Dr. Ailia served as an internal medicine specialist at Bezmialem Vakıf University Hospital. From 2023 to 2024, Dr. Ailia was an instructor in medical oncology at Başkent University Adana Dr. Turgut Noyan Practice and Research Center.

Clinical focus includes breast, lung, and prostate cancers. It also covers gastrointestinal cancers (colon, stomach, esophagus, pancreas, liver), lymphomas, melanoma, and gynecologic and genitourinary cancers. Languages: English, Turkish, Swahili.

O Dr. Eytan Aharon Ben-Ami lidera a Divisão de Oncologia no Centro Médico Sheba, em Israel. Especializou-se em sarcomas e oncologia óssea no Dana-Farber Cancer Institute. O Dr. Ben-Ami fundou a Organização de Pesquisa Clínica Sheba para promover estudos sobre o câncer. Ele trata tumores ósseos raros e sarcomas de tecidos moles com protocolos personalizados.

• Chefia a Unidade de Ensaios Clínicos de Fase Inicial para terapias inovadoras contra o câncer.
• Autor de mais de 40 publicações científicas sobre mecanismos moleculares e detecção precoce.
• Lidera ensaios de Fase I em terapia direcionada e imunoterapia para cânceres raros.
• Trabalha no Centro Médico Sheba, um dos 10 melhores hospitais do mundo segundo a Newsweek.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

O Dr. Jair Bar é oncologista torácico e vice-diretor do Centro de Câncer do Sheba Medical Center. Ele é especializado no tratamento de câncer de pulmão de células não pequenas avançado usando imunoterapia personalizada e tratamentos direcionados. O Dr. Bar possui doutorado em Biologia Molecular e lidera um laboratório de pesquisa focado em resistência à imunoterapia.

• Presidente do Grupo Israelense de Câncer de Pulmão.
• Certificado em Oncologia Médica e Radioterapia Oncológica.
• Trata pacientes no Sheba Medical Center, um dos 10 melhores hospitais do mundo.
• Usa perfil molecular e genético para criar planos precisos de tratamento contra o câncer.

O Dr. Nir Kleinmann dirige a Unidade de Endourologia e Cálculos Renais no Sheba Medical Center. Ele é pioneiro em cirurgia a laser de preservação renal para tumores complexos. A Forbes e a ResultMed nomearam-no entre os melhores médicos de Israel para 2025 e 2026. O Dr. Kleinmann utiliza um sistema de laser duplo exclusivo para preservar a função orgânica durante o tratamento do cancro.

• Completou bolsas de urologia na Universidade Thomas Jefferson e na Universidade McMaster.
• Especialista em tratamentos minimamente invasivos para UTUC, cálculos renais e cancro da próstata.
• Atuou como investigador no ensaio OLYMPUS para quimioablação não cirúrgica.
• Membro da Sociedade Americana de Endourologia com mais de 60 publicações científicas.

O Dr. Zohar Dotan chefia o departamento de urologia no Sheba Medical Center. Ele utiliza diagnósticos PET/CT para planejar cirurgias precisas para câncer de próstata e rim.

• Formado em uro-oncologia no Memorial Sloan Kettering Cancer Center em Nova York
• Ex-chefe da Sociedade Israelense de Uro-Oncologia
• Recebedor de prêmios da Associação Americana de Cirurgia Clínica
• Autor de mais de 50 publicações científicas sobre tratamento e pesquisa de câncer
• Professor assistente na Faculdade de Medicina da Universidade de Tel Aviv

Udom Nuchintra — radiologia diagnóstica, Pacific Garden Hospital.

O Dr. Yaacov Lawrence é o Chefe de Oncologia Radioterápica no Centro Médico Sheba. Ele é especializado em radioterapia de precisão e neuro-oncologia. O Dr. Lawrence foi pioneiro na radiocirurgia do plexo celíaco para o controle da dor no câncer de pâncreas. Ele possui a designação FASTRO, uma das mais altas honrarias em sua especialidade.

• Lidera o Programa de Câncer Gastrointestinal no Centro Médico Sheba.
• Realiza radiocirurgia estereotática para tumores cerebrais e cânceres do sistema nervoso.
• Autor de mais de 280 publicações científicas sobre protocolos de radiação personalizados.
• Concluiu o treinamento de fellowship em oncologia radioterápica na Universidade Thomas Jefferson.

O Professor Lee especializa-se em distúrbios pancreatobiliares no Samsung Medical Center. Ele utiliza imagens de PET/CT para avaliar cancros do pâncreas, vias biliares e vesícula biliar.

• Formado na Universidade Nacional de Seul e na Universidade da Califórnia
• Especialista na gestão de casos complexos de oncologia abdominal
• Realiza cirurgias avançadas, como o procedimento de Whipple
• Membro da Sociedade Coreana de Endoscopia Gastrointestinal
• Trata pacientes numa instalação que cumpre os padrões presidenciais na Coreia do Sul

O Dr. Choi Han Yong lidera o Departamento de Urologia no Samsung Medical Center. Ele utiliza imagens de PET/CT para orientar o planejamento cirúrgico de cânceres urológicos complexos.

• Atua como Chefe de Urologia em um dos hospitais mais bem classificados da Coreia do Sul
• Especializado em cirurgia oncológica de próstata, rim e bexiga
• Fornece interpretação especializada de imagens para localização precisa de tumores
• Membro das principais sociedades urológicas e oncológicas internacionais

O Professor Kim Tae Joong é especialista em oncologia ginecológica no Samsung Medical Center. Ele utiliza imagens de PET/CT para detectar e estadiar cânceres do sistema reprodutor feminino.

• Foca na identificação de tumores e no acompanhamento do progresso do tratamento usando imagens avançadas
• Especialista em cuidados oncoginecológicos em um dos hospitais mais bem classificados da Coreia do Sul
• Professor na Faculdade de Medicina da Universidade Sungkyunkwan
• Membro da Sociedade Coreana de Oncologia Ginecológica

O Dr. Lee Jeong Won é oncoginecologista no Samsung Medical Center. Ele utiliza ferramentas como PET/CT para detectar e monitorar cânceres ginecológicos.

• Especializado em oncoginecologia – diagnóstico e tratamento de cânceres do sistema reprodutor feminino
• Atua no Samsung Medical Center – um hospital de primeira linha na Coreia do Sul
• Utiliza diagnóstico por imagem para identificar a localização de tumores e sua propagação no corpo

O Dr. Seung Jae Huh é oncologista no Samsung Medical Center. Ele utiliza imagens de PET/CT para a detecção precisa do câncer e planejamento do tratamento.

• Atua no Samsung Medical Center – um hospital líder em oncologia na Coreia do Sul
• Foca em imagem oncológica para o estadiamento preciso de tumores
• Trabalha em um departamento de oncologia especializado para casos complexos de câncer

O Dr. Lee é especializado em oncologia gastrointestinal no Samsung Medical Center. Ele foca no diagnóstico e tratamento de cânceres de pâncreas, ductos biliares e vesícula biliar.

• Formado na Stanford University School of Medicine nos Estados Unidos
• Utiliza exames PET/CT para avaliar casos de câncer de pâncreas e cólon
• Professor de Gastroenterologia em uma faculdade de medicina sul-coreana de destaque
• Membro da Sociedade Coreana de Endoscopia Gastrointestinal
• Completou treinamento clínico avançado no Kyoto Second Red Cross Hospital

Mais de 15.000 procedimentos cirúrgicos realizados – O Dr. de Lacy Fortuny lidera a inovação cirúrgica no Hospital Quiron Barcelona.

• Presidente da Associação Europeia de Cirurgiões Endoscopistas
• Desenvolveu a técnica TaTME para cirurgia de alta precisão do cancro retal
• Utiliza resultados de PET/CT para planear tratamentos minimamente invasivos de cancro gastrointestinal
• Pioneiro na remoção de órgãos através de orifícios naturais do corpo
• Orador internacional sobre métodos cirúrgicos robóticos e laparoscópicos avançados

O Dr. Erkan Karatas é cirurgião otorrinolaringologista e maxilofacial no Hospital Universitário Atlas, em Istambul. Especializa-se em cirurgia da base do crânio e colocação de implantes cocleares. O Dr. Karatas contribuiu para mais de 100 artigos médicos. Concluiu formação especializada em centros de prestígio nos EUA, Alemanha, Itália e Suíça.

• Membro de 11 associações profissionais, incluindo a Academia Americana de Otorrinolaringologia.
• Especialista em cirurgias complexas de cancro da tiroide, língua e laringe.
• Realiza procedimentos especializados como estapedectomia, timpanoplastia e cirurgia ortognática.
• Trabalha num hospital acreditado pela AACI que trata 565.000 pacientes anualmente.